Niagen Bioscience, Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
NAGE$2.15-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and
Unaudited Condensed Consolidated Balance Sheets
(In thousands except par values, unless otherwise indicated)
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents, including restricted cash of $152 for both periods presented | $60,474 | $44,660 |
| Trade receivables, net of allowances of $199 and $95, respectively | 9,656 | 7,768 |
| Inventories | 14,406 | 9,192 |
| Prepaid expenses and other assets | 2,143 | 2,482 |
| Total current assets | 86,679 | 64,102 |
| Leasehold improvements and equipment, net | 1,632 | 1,719 |
| Intangible assets, net | 284 | 359 |
| Right-of-use assets, net | 2,525 | 1,730 |
| Other long-term assets | 405 | 368 |
| Total assets | $91,525 | $68,278 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities | ||
| Accounts payable | $13,680 | $8,526 |
| Accrued expenses | 7,381 | 7,817 |
| Current maturities of operating lease obligations | 957 | 982 |
| Current maturities of finance lease obligations | 6 | 12 |
| Customer deposits | 303 | 611 |
| Total current liabilities | 22,327 | 17,948 |
| Deferred revenue | 2,674 | 2,579 |
| Operating lease obligations, less current maturities | 2,329 | 1,657 |
| Total liabilities | 27,330 | 22,184 |
| Commitments and Contingencies (Note 10) | ||
| Stockholders' Equity | ||
| Common stock, $0.001 par value; authorized 150,000 shares; 79,586 shares and 77,330 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | 79 | 77 |
| Additional paid-in capital | 237,358 | 227,931 |
| Accumulated deficit | (173,238) | (181,910) |
| Cumulative translation adjustments | (4) | (4) |
| Total stockholders' equity | 64,195 | 46,094 |
| Total liabilities and stockholders' equity | $91,525 | $68,278 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.